Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Leukemia Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LILRB4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LILRB4 ECD-Fc Fusion Protein High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View LILRB4 Products |
| Gene Delivery | LILRB4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based conformation assays. |
View LILRB4 Products |
| Benchmark Ab | Anti-LILRB4 Recombinant Antibody Recombinant positive control derived from clinical-stage sequences (e.g., IO-202 analog). |
View LILRB4 Products |
| Validator | LILRB4 siRNA Set Target-specific knockdown verification in primary myeloid cells or AML cell lines. |
View LILRB4 Products |
| Related Target A | APOE Primary functional ligand of LILRB4; crucial for validating ligand-blocking therapeutic mechanisms. |
View APOE Products |
| Related Target B | LILRB2 Close homolog within the LILR family; essential for counter-screening to ensure candidate specificity. |
View LILRB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| APOE Ligand Binding Validation | HEK293-expressed LILRB4 with native post-translational modifications, ensuring physiological binding affinity. |
| LILR Family Off-Target Profiling | Cross-reactivity panels including LILRB1, LILRB2, and LILRB5 strictly verified by SDS-PAGE and Mass Spectrometry. |
| Lack of Validated Controls | Sequence-verified clinical benchmark biosimilar antibodies included for assay calibration. |
| Inconsistent Cell-Line Expression | High-titer Lentiviral vectors for stable, high-density LILRB4 expression in target host cells. |
Live LILRB4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LILRB4 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to bispecific constructs and antibody-drug conjugates (ADCs). As first-generation myeloid checkpoint inhibitors reach the clinic, the next wave of R&D is targeting the reversal of immune suppression in cold solid tumors and direct tumor-killing in monocytic AML.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Immune-Onc Therapeutics, NextCure | AML, MDS, Solid Tumors | Blocking assays (Requires high-purity LILRB4 and APOE proteins) |
| Bispecific / T-Cell Engager | Merck, Various Biotechs | Hematological Malignancies | Dual-targeting validation (Requires stable LILRB4-expressing cell lines via Lentivirus) |
| Antibody-Drug Conjugate (ADC) | Invenra, Academic Consortia | Acute Myeloid Leukemia (AML) | Internalization assays (Requires sequence-verified, endotoxin-controlled target antigens) |